Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma

Figure 1 Overview of study design. HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; miRNA: Micro ribonucleic acid; NGS: Next-generation sequencing; RT-qPCR: Real-time quantitative PCR.

Figure 2 Overview of the two-tier cross-validation workflow employing logistic regression.

Figure 3 Receiver operating characteristics curves and area under the curve for multivariate analysis of real-time quantitative PCR results. A: Comparison of all hepatocellular carcinoma vs chronic liver disease; B: Early hepatocellular carcinoma vs chronic liver disease; C: Early hepatocellular carcinoma vs cirrhosis. Analyses were for the validation cohort. Upper panel: Protein induced by vitamin K absence/antagonist-II alone; Lower panel: Protein induced by vitamin K absence/antagonist-II in combination with the best miRNA (selected as final pair in the training analysis). AUC: Area under the curve; CI: Confidence interval; CLD: Chronic liver disease; HCC: Hepatocellular carcinoma; miR: MicroRNA; PIVKA-II: Protein induced by vitamin K absence/antagonist-II.